XIFAXAN was given a strong recommendation† to treat global IBS-D symptoms in the 2020 ACG Clinical Guideline on Managing IBS5,‡
‡Based on a moderate quality of evidence§
- ACG, American College of Gastroenterology.
- †Strength of recommendation: Strong=Most patients should
- receive the recommended course of action; Conditional=Many
- patients should have this recommended course of action, but
- different choices may be appropriate for some patients.
- §Summary of quality of evidence:
- High=The estimate of effect is unlikely to change with new data.
- Moderate=The estimate of effect is uncertain.
- Questions and statements used to provide recommendations were based on response to global IBS-D symptoms.
- ACG, American College of Gastroenterology.
- †Strength of recommendation: Strong=Most patients should receive the recommended course
of action; - Conditional=Many patients should have this recommended course of action, but different choices may be appropriate for some patients.
- §Summary of quality of evidence:
- High=The estimate of effect is unlikely to change with new data. Moderate=The estimate of effect is uncertain.
- Questions and statements used to provide recommendations were based on response to
global IBS-D symptoms.